While maintaining its 'weight in line' recommendation, Barclays raises its target price on Ipsen from 125 to 135 euros, adjusting operating expense forecasts for the healthcare group to reflect less impact from generic erosion.

Also adjusting its Onivyde sales estimates to reflect an extended patent life to 2033, and updating its first-quarter earnings guidance, the broker says it is in line with consensus and above guidance for 2024.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.